Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Mathias Warm Ronald Kates Friedrich Overkamp Anke Thomas Nadia Harbeck
- چاپ و سال / کشور: 2010
Description
Response to fulvestrant and survival in postmenopausal hormone-sensitive advanced breast cancer was investigated within a non-randomized, In-Practice Evaluation Program, with the aim of optimizing treatment decisions. 848 patients (median age 64 years; 52% co-morbidity; 78% prior palliative therapy; median 4 prior regimens) received monthly fulvestrant injections (250 mg/month) and were followed-up three-monthly for 9 months. Clinical benefit (PFS C 24 weeks) occurred in 532/848 (62.7%); stable disease (SD) in 627/848 patients (74%), including 62 complete and 177 partial responses. Best response was delayed in 115 patients. Estimated 9-month overall survival (OS) was 89%; 9-month event-free survival (EFS) was 71%. Indicators of disease aggressiveness affected response and survival, but number of fulvestrant cycles was the key OS and EFS determinant. The patients with SD at 3 months benefitted from continued fulvestrant. Excluding deaths, 7 serious adverse events occurred (none attributable to fulvestrant). No new or unexpected safety issues arose; 90% of the patients and physicians rated fulvestrant tolerability as ‘‘very good’’ or ‘‘good’’. In the largest prospective, fulvestranttreated cohort to date, advanced breast cancer patients achieving SD or better after 3 months of treatment gained survival benefit by prolonging fulvestrant therapy—independent of disease and treatment history.
Breast Cancer Res Treat (2011) 125:127–136 DOI 10.1007/s10549-010-1214-3 Received: 13 July 2010 / Accepted: 4 October 2010 / Published online: 20 October 2010 Springer Science+Business Media, LLC. 2010
